去势抵抗性前列腺癌:AUA指南2018年修正版
该修正版纳入新发表文献,聚焦非转移性去势抵抗性前列腺癌(CRPC)的治疗。2018年修正检索获得770篇参考文献,最终47项研究提供相关数据,新增无症状非转移性CRPC的指南声明。指南强调共享决策并需结合近期系统综述与患者个体治疗目标使用。
要点
- 2018年修正检索770篇参考文献,47项研究提供相关数据。
- 新增无症状非转移性CRPC的指南声明,并更新现有支持文本。
- 指南应结合近期系统综述与患者个体治疗目标使用,强调共享决策。
核心结论
- 该指南应结合近期系统文献综述及对患者个体治疗目标的理解使用。
- 选择管理策略时应实施纳入患者偏好与个人目标的共享决策。
- 该指南将随新文献出现而持续更新。
研究设计与样本
- 原始系统综述与荟萃分析纳入1996年至2013年发表的303项研究,构成2013版指南多数声明的基础。
- 指南随后于2014年4月和2015年3月修正;2018年修正检索获得770篇参考文献,最终47项研究提供相关数据。
主要发现
- 2018年修正聚焦纳入非转移性CRPC患者治疗相关信息。
- 基于代表临床实践最常见场景的6个索引患者制定的指南声明被适当修正。
- 新增文献为更新现有支持文本及纳入无症状非转移性CRPC的新指南声明提供了依据。
关键数值与推荐
- 缺乏充分证据的指南声明采用临床原则与专家意见。
- 基于6个索引患者制定的指南声明经适当修正,以代表临床实践最常见场景。
临床怎么用
- 临床管理非转移性CRPC时应结合近期系统文献综述与患者个体治疗目标。
- 选择管理策略时应实施纳入患者偏好与个人目标的共享决策。
- 该指南需随新文献出现持续更新,临床应关注后续版本。
局限性
- 缺乏充分证据的指南声明依赖临床原则与专家意见。
- 该领域发展迅速,指南需与近期系统文献综述结合使用并持续更新。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of this amendment is to incorporate newly-published literature to provide a rational basis for the management of patients with non-metastatic castration-resistant prostate cancer (CRPC). MATERIALS AND METHODS: The original systematic review and meta-analysis of the published literature yielded 303 studies published from 1996 through 2013. This review informed the majority of the guideline statements from the 2013 guideline. Clinical Principles and Expert Opinions were used for guideline statements lacking sufficient evidence. The guideline was subsequently amended in April 2014 and March 2015. The current 2018 amendment search yielded 770 references with 47 studies eventually providing relevant data. The resulting amendment focuses on the incorporation of information relating to the treatment of patients with non-metastatic CRPC. RESULTS: Guideline statements based on six Index Patients developed to represent the most common scenarios encountered in clinical practice were amended appropriately. The additional literature provided the basis for an update of current supporting text as well as the incorporation of new guideline statements for asymptomatic non-metastatic CRPC. CONCLUSIONS: Given the rapidly evolving nature of this field, this guideline should be used in conjunction with recent systematic literature reviews and an understanding of individual patients' treatment goals. Shared decision-making incorporating patients' preferences and personal goals should be implemented when choosing management strategies. This guideline will be continually updated as new literature emerges.
引用
- Lowrance WT, Murad MH, Oh WK, et al. Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018. J Urol. 2018. PMID: 30086276. doi:10.1016/j.juro.2018.07.090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。